Why Regeneron Pharmaceuticals stock moves
Regeneron Pharmaceuticals was roughly unchanged, an ordinary day.
Written after the close on ·
Why today
16,413 news analyzed todayRegeneron Pharmaceuticals was roughly unchanged, an ordinary day.
The shares moved less than the S&P 500, which rose slightly.
No company news clearly explains the session, though trading volume was about twice normal.
Earlier this week the stock fell clearly with the market, which also dropped sharply over the five days.
Insider share sales by a director were reported, but these are background and not the cause.
Today's move of +0.16% was 0.1 times a normal day's 1.1%. S&P 500 moved +0.31% on the same day.
Regeneron Pharmaceuticals +0.16%S&P 500 +0.31%In step with the market
What analysts expect, and how often they have been right
Analysts’ estimates for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals earned more than expected in 7 out of 8 reports.
For comparison, about 82% of reports from US companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 6 out of 8 reports with a measured move, against about 55% of reports from US companies.
Ratings
Price targets
Latest price $904.35
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expected$
Next reported quarter: expected earnings per share of $25.39 (January 28). For the current fiscal year, expected earnings per share changed from $53.00 three months ago to $68.75 now. 2026 estimate: $68.75. 2027 estimate: $62.12.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across US companies, that happens in about 65% of years. In 2025, the price changed +8% and earnings per share +8%.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.$B
Assets, liabilities and market cap
AssetsLiabilitiesMarket cap$B
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): $93.6BRevenue 2025: $14.3B
What the key figures say about Regeneron Pharmaceuticals
The figures connect what Regeneron Pharmaceuticals earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: $34.77–$41.48. Peers: Moderna -$7.04, Vertex Pharmaceuticals $15.54, Genmab 75.25 DKK. 2026 estimate: $68.75 ($61.35–$74.53). 2027 estimate: $62.12 ($54.89–$73.76).
What the company sold during the year.
2022–2025: $12.2B–$14.3B. Peers: Moderna $2.5B, Vertex Pharmaceuticals $13.0B, Genmab $4.3B. 2026 estimate: $18.8B ($17.8B–$19.5B). 2027 estimate: $20.1B ($17.3B–$21.7B).
The percentage of revenue left after the costs of running the business.
2022–2025: 25.8%–38.9%. Peers: Moderna −150.2%, Vertex Pharmaceuticals 33.1%, Genmab 30.6%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: 14.4%–19.1%. Peers: Moderna −34.5%, Vertex Pharmaceuticals 20.8%, Genmab 12.1%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 18.6–25.3. Peers: Vertex Pharmaceuticals 35.2, Genmab 46.9. 2026 estimate: 13.2. 2027 estimate: 14.6.
What investors pay for each unit the company sells.
2022–2025: 5.50–7.33. Peers: Moderna 40.73, Vertex Pharmaceuticals 10.71. 2026 estimate: 4.98. 2027 estimate: 4.64.
Money paid to shareholders per share, summed by calendar year.
2025–2025: $3.52–$3.52.
The ordinary yearly dividend as a percentage of the share price.
2022–2025: 0.0%–0.5%. Peers: Moderna 0.0%, Vertex Pharmaceuticals 0.0%, Genmab 0.0%.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: -1.73–-0.96. Peers: Vertex Pharmaceuticals 0.03, Genmab 2.45.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 2.61–3.70. Peers: Moderna 11.58, Vertex Pharmaceuticals 6.63.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 14.4–20.6.
Cash left after investments, divided by the number of shares.
2022–2025: $31.00–$35.62. Peers: Moderna -$3.07, Vertex Pharmaceuticals $12.63, Genmab $13.71.
The percentage of assets financed by shareholders’ equity.
2022–2025: 77.1%–78.5%.
The dividend explained
A dividend is money paid to shareholders. Regeneron Pharmaceuticals paid $3.70 per share in the twelve months through November 6, 2026.
On the ex-dividend day, August 18, 2026, Regeneron Pharmaceuticals traded without the right to the $0.94 dividend. The price went from $805.93 to $810.24; including the dividend, the day's change was +0.7%. Entitlement passes from the company to shareholders on the ex-day; payment comes later.
2025: $3.522026 so far: $2.82
What to watch next, and why
From the ex-day, Regeneron Pharmaceuticals trades without entitlement to the next dividend.
- The dividend explained
From the ex-day, Regeneron Pharmaceuticals trades without entitlement to the next dividend.
- Earnings report
The earnings report shows how Regeneron Pharmaceuticals's revenue and profit have changed.
Add to calendar
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Regeneron Pharmaceuticals usually moved about 5.4%. On a normal day it moves 1.1%.
+13.33% Why? +6.17% −6.21% −1.07%
$10,000 in Regeneron Pharmaceuticals bought on November 7, 2016 is worth $25,000 today, with dividends reinvested.
The same amount in S&P 500 with dividends would have become $40,400.
What would $10,000 in Regeneron Pharmaceuticals be worth today? →
What would $10,000 in Regeneron Pharmaceuticals be worth today?
$25,000
with dividends reinvested, bought on November 7, 2016. The same amount in S&P 500 with dividends would have become $40,400.
At worst it was worth $7,480 (September 27, 2019).
The five biggest days of the journey
· −19.0% · the whole market was unchanged the same day
· +18.8% · the whole market rose 0.7% the same day
· +13.8% · the whole market rose 1.1% the same day
· +13.3% · the whole market fell 1.8% the same day · report day · Why?
· +11.8% · the whole market rose 0.2% the same day · report day
Earlier days
−2.54% market −2.70% Regeneron Pharmaceuticals fell clearly over the week, moving in line with the broader market, which also fell sharply. Read →
Regeneron Pharmaceuticals fell clearly over the week, moving in line with the broader market, which also fell sharply.
Its trading was heavier than usual, about twice a normal session.
Over the same days the market fell sharply, which suggests broad market selling played a large part.
−2.98% market −4.41% Regeneron fell, moving in line with the market. Read →
Regeneron fell, moving in line with the market.
The S&P 500 also fell very sharply, and the Healthcare sector ETF fell very sharply too.
No single company news explains the session's fall, and trading volume ran well above its usual level.
−4.39% market +1.65% Regeneron Pharmaceuticals fell, moving against the market. Read →
Regeneron Pharmaceuticals fell, moving against the market.
No clear company news explains it.
The stock had a very big move, and trading volume was well above its usual level.
Over the last five trading days, the shares rose very sharply, far more than the healthcare sector ETF, an exchange-traded fund that tracks the sector.
+1.26% market +0.30% Regeneron Pharmaceuticals rose, a big move for this stock. Read →
Regeneron Pharmaceuticals rose, a big move for this stock.
Regeneron Pharmaceuticals rose clearly in the last session while the S&P 500 rose slightly.
Likely drivers: a Leerink Partners price target raise to $9 and a strong trading day.
A director's planned share sale was filed, but it is background, not a cause.
Over five trading days the stock rose very sharply while the S&P 500 fell clearly, and the healthcare sector ETF rose sharply.
+3.60% market −0.48% Regeneron Pharmaceuticals rose, moving against a market that fell slightly. Read →
Regeneron Pharmaceuticals rose, moving against a market that fell slightly.
The stock's rise came with heavy trading, about three times a normal session, and the healthcare sector was roughly flat that day.
Company news came out before the session opened, when Regeneron Pharmaceuticals reported third-quarter results that beat expectations and posted strong sales growth for its key medicines.
The stock rose sharply over the last five trading days, a very big move, about seven times a normal five-day stretch, and moves that large did not occur in the past year.
+13.33% market −1.77% Regeneron Pharmaceuticals rose very sharply. Read →
Regeneron Pharmaceuticals rose very sharply.
Regeneron Pharmaceuticals rose, while the S&P 500 fell sharply, so it moved strongly against the market.
Its moves in the last session were very big, about 12 times a normal day, and no move that size happened in the past year.
Trading volume was well above its usual level, about five times a normal session.
Shares rose sharply after new Phase 3 data showed adjuvant Libtayo cut the risk of death in high-risk skin cancer by up to 37%, with disease-free survival sustained for nearly four years, and after several analysts raised their price targets, the share price they see as fair.
+15.26% market −0.56% Regeneron Pharmaceuticals rose very sharply over the week's trading days, a very big move for the stock. Read →
Regeneron Pharmaceuticals rose very sharply over the week's trading days, a very big move for the stock.
While the S&P 500 fell slightly, Regeneron moved strongly against the market and well ahead of its healthcare sector.
The main driver was the Friday rally on new Libtayo skin cancer data, which showed longer survival, plus raised analyst price targets.
Its earnings also beat expectations on 30 October.
+0.68% market −0.38% Regeneron Pharmaceuticals rose slightly without company news. Read →
Regeneron Pharmaceuticals rose slightly without company news.
The S&P 500 fell slightly that day, so the stock moved against the market.
Over the last five trading days the stock was roughly unchanged, while the S&P 500 rose slightly and the Healthcare sector ETF rose clearly.
Thursday's move was an ordinary one for the stock.
Its earnings report is due Friday 30 October 2026, and the Q3 earnings preview and analyst price target raises published before the session are the most relevant background, though they were not the cause of Thursday's move.
+1.81% market −0.43% Regeneron Pharmaceuticals rose slightly over the last five trading days, while the broader market fell slightly. Read →
Regeneron Pharmaceuticals rose slightly over the last five trading days, while the broader market fell slightly.
The stock moved against the S&P 500 but in line with its healthcare sector, which rose clearly.
Analysts including TD Cowen and Piper Sandler raised their price targets, meaning the share prices they see as fair value, during the week.
Investors also looked ahead to the company's quarterly earnings report due on Friday, 30 October.
+3.25% Regeneron Pharmaceuticals rose sharply, in line with its sector. Read →
Regeneron Pharmaceuticals rose sharply, in line with its sector.
Its sector, healthcare, rose very sharply over the same days, while the S&P 500 fell, so the stock moved against the broader market.
The most likely driver is the sector-wide rally, with company news adding to it; a Libtayo dosing update from the European medicines regulator and long-term Pasatru trial data came out earlier this week.
Over the last five trading days the move was big, about three times a normal stretch for this stock, a size seen roughly nine times in the past year.
+2.31% market +0.28% Regeneron Pharmaceuticals rose clearly, on news about its drug Pasatru and an expanded immunology deal with Sanofi. Read →
Regeneron Pharmaceuticals rose clearly, on news about its drug Pasatru and an expanded immunology deal with Sanofi.
The gain was larger than the market's and in line with the healthcare sector.
Pasatru is a treatment for fibrodysplasia ossificans progressiva, a rare disorder that causes bone to form in muscles and tendons.
Positive trial data for a drug like this can raise investor expectations for future sales, which often lifts a biotech stock.
The expanded partnership with Sanofi, a large drugmaker, adds to that view by sharing development costs and widening the company's pipeline.
+3.35% market −1.08% Regeneron Pharmaceuticals rose sharply, moving against a falling S&P 500 and in line with a Healthcare sector that rose very sharply; the most likely reason is a UBS upgrade to Buy, which argues that Dupixent's future is undervalued and that its exclusivity runs to 2031 or later. Read →
Regeneron Pharmaceuticals rose sharply, moving against a falling S&P 500 and in line with a Healthcare sector that rose very sharply; the most likely reason is a UBS upgrade to Buy, which argues that Dupixent's future is undervalued and that its exclusivity runs to 2031 or later.
Over the last five trading days the stock rose clearly while the S&P 500 slipped slightly, so the gain was company-led rather than market-led.
Dupixent is the key drug Regeneron shares with its partner Sanofi, so its growth carries much of the valuation.
Some of the recent strength also likely reflects investor attention to Regeneron's share of Sanofi collaboration profits, which it now records in full now that repayment of an old balance has finished.
The next earnings report is due Friday 30 October 2026, where the expected step-up in Sanofi collaboration revenue would be tested.
+2.18% market −0.06% Regeneron rose clearly, lifted by strong trial data. Read →
Regeneron rose clearly, lifted by strong trial data.
Regeneron Pharmaceuticals climbed sharply over the last five trading days, outpacing both a slightly higher market and a sharply higher healthcare sector.
The likely driver was fresh late-stage trial news for its rare bone-disease drug Pasatru — a treatment for fibrodysplasia ossificans progressiva, a condition where soft tissue turns to bone — showing no new abnormal bone growth in an extension study, alongside an expanded antibody alliance with Sanofi worth a large upfront payment.
Analyst target-price increases and anticipation of a late-October earnings report likely added support.
Watch the upcoming earnings report and any further pipeline readouts for direction.
Learn more · Why do stocks go up and down?